Trial Profile
Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloidosis; Familial amyloid neuropathy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Aug 2020 Status changed from active, no longer recruiting to completed.
- 24 Apr 2020 Planned End Date changed from 31 Dec 2021 to 30 May 2020.
- 24 Apr 2020 Planned primary completion date changed from 31 Dec 2021 to 30 May 2020.